Results 241 to 250 of about 44,847 (272)

Possible involvement of nitroglycerin converting step in nitroglycerin tolerance

Life Sciences, 1999
Nitroglycerin (GTN) produces a dilation of vascular smooth muscle by releasing NO through a putative GTN-converting step. However, the response to GTN is markedly attenuated after prolonged or repeated exposure, resulting in tolerance. We investigated the mechanisms of GTN tolerance, employing exogenous and endogenous NO in rat aorta.
Ikunobu Muramatsu, Koichi Hasegawa, Ko Takakura, Takanobu Taniguchi, Yukio Goto   +4 more
openaire   +3 more sources

Pharmacokinetics of Nitroglycerin in Rats

Journal of Pharmaceutical Sciences, 1978
The plasma nitroglycerin levels obtained after intracardial (0.7 mg/kg), oral (7 mg/kg), and topical (7--14 mg/kg) doses of nitroglycerin in rats are reported. Nitroglycerin followed essentially one-compartment kinetics after intracardial administration, showing a mean half-life of about 4 min and a mean apparent volume of distribution of about 3 ...
Peter S.K. Yap, Ho-Leung Fung
openaire   +3 more sources

Pharmaceutical Considerations of Nitroglycerin

Drug Intelligence & Clinical Pharmacy, 1983
During the past few years, there have been rapid changes in the pharmaceutical uses of nitroglycerin. New dosage forms and new delivery systems have become available, which have resulted in potential confusion to all concerned with the proper use of these systems.
Anton H. Amann, David M. Baaske, Avraham Yacobi   +2 more
openaire   +3 more sources

Nitroglycerin for Angina Pectoris

JAMA, 1978
To the Editor.— As a physician responsible for the long-term care of patients with coronary disease, I welcomed the recent comments of Oglesby Paul, MD, on the medical management of angina pectoris (238:1847, 1977). I agreed particularly with his skepticism about the value of long-acting nitrates.
openaire   +3 more sources

Bioactivation of Nitroglycerin by Ascorbate

Molecular Pharmacology, 2007
Bioactivation of nitroglycerin (GTN) into an activator of soluble guanylate cyclase (sGC) is essential for the vasorelaxant effect of the drug. Besides several enzymes that catalyze GTN bioactivation, the reaction with cysteine is the sole nonenzymatic mechanism known so far. Here we show that a reaction with ascorbate results in GTN bioactivation.
Matteo Beretta, Alexander Kollau, Michael Russwurm, Antonius C. F. Gorren, Doris Koesling, Bernd Mayer, Kurt Schmidt   +6 more
openaire   +3 more sources

Intravenous Nitroglycerin

AJN, American Journal of Nursing, 1982
J A, Purcell, C K, Holder
  +8 more sources

Nitroglycerin for Neurosurgery

Journal of Neurosurgery, 1978
Robert M. Crowell, Nicholas T. Zervas, Guillermo Candia, Joerg Kistler, Robert G. Ojemann, R S Lees   +5 more
openaire   +3 more sources

Nitroglycerin and methemoglobinemia

The American Journal of Cardiology, 1986
Kerry Kaplan, Richard Davlson
openaire   +3 more sources

Intravenous nitroglycerin

American Heart Journal, 1978
J E, Cottrell, H, Turndorf
openaire   +4 more sources

Nitroglycerin and potassium

The American Journal of Cardiology, 1986
J. Gerald Toole, Thomas J. Kleinhenz
openaire   +3 more sources